200,000+ products from a single source!
sales@angenechem.com
114466-38-5 | 1-29-Somatoliberin (human pancreatic islet), 29-L-argininamide-, acetate (salt), hydrate (9CI)
CAS No: 114466-38-5 Catalog No: AG000EGP MDL No:MFCD08277636
Product Description
Catalog Number:
AG000EGP
Chemical Name:
1-29-Somatoliberin (human pancreatic islet), 29-L-argininamide-, acetate (salt), hydrate (9CI)
CAS Number:
114466-38-5
MDL Number:
MFCD08277636
IUPAC Name:
acetic acid;(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChI:
InChI=1S/C149H246N44O42S.C2H4O2/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158;1-2(3)4/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165);1H3,(H,3,4)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-;/m0./s1
InChI Key:
BVLCEKWPOSAKSZ-YQMCHIOTSA-N
Properties
Complexity:
7670
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
31
Defined Bond Stereocenter Count:
0
Exact Mass:
3416.843g/mol
Formal Charge:
0
Heavy Atom Count:
240
Hydrogen Bond Acceptor Count:
51
Hydrogen Bond Donor Count:
53
Isotope Atom Count:
0
Molecular Weight:
3417.985g/mol
Monoisotopic Mass:
3415.84g/mol
Rotatable Bond Count:
118
Topological Polar Surface Area:
1510A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. | Behavioural brain research 20120801 |
| Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice. | Behavioural brain research 20120715 |
| Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. | The Prostate 20120401 |
| Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. | The Journal of urology 20120401 |
| Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71. | Behavioural brain research 20120317 |
| Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. | Cancer 20120201 |
| Inhibition of GHRH aggravated acetaminophen-induced acute mice liver injury through GH/IGF-I axis. | Endocrine journal 20120101 |
| GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. | Cell cycle (Georgetown, Tex.) 20111101 |
| Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. | Behavioural brain research 20111010 |
| The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. | International journal of oncology 20111001 |
| Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20111001 |
| Growth hormone releasing hormone induces the expression of nitric oxide synthase. | Journal of cellular and molecular medicine 20110501 |
| Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21. | Cancer letters 20101201 |
| The effect of GHRH antagonists on human glioblastomas and their mechanism of action. | International journal of cancer 20101115 |
| GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. | Cancer letters 20100701 |
| Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. | The Prostate 20100701 |
| Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. | Journal of molecular endocrinology 20100201 |
| Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. | Reproductive biology and endocrinology : RB&E 20100101 |
| Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. | Neuropeptides 20091001 |
| GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. | Cell cycle (Georgetown, Tex.) 20091001 |
| Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. | Breast cancer research and treatment 20090701 |
| Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. | The Prostate 20081201 |
| Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. | Journal of molecular endocrinology 20081101 |
| Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. | Oncology reports 20081101 |
| Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. | British journal of cancer 20080603 |
| Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. | International journal of oncology 20080301 |
| The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. | The Prostate 20070901 |
| Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. | International journal of oncology 20070401 |
| Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? | Clinical interventions in aging 20061201 |
| Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. | Clinical endocrinology 20061001 |
| Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix. | Journal of controlled release : official journal of the Controlled Release Society 20050902 |
| Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. | The Prostate 20050801 |
| Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. | European journal of endocrinology 20050801 |
| Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. | Endocrinology 20050701 |
| Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. | The Journal of clinical endocrinology and metabolism 20050601 |
| Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050101 |
| Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. | European journal of endocrinology 20041101 |
| Potent trypsin-resistant hGH-RH analogues. | Journal of peptide science : an official publication of the European Peptide Society 20040801 |
| Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 20040601 |
| Effect of growth hormone-releasing hormone (GHRH) and GHRH antagonist (MZ-4-71) on interferon-gamma secretion from human peripheral blood mononuclear cells in vitro. | Neuropeptides 20040201 |
| Dietary n-3 and n-6 fatty acids alter avian pituitary sensitivity. | Nutritional neuroscience 20031201 |
| Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. | Cancer research 20031115 |
| Disparate regulation of insulin-like growth factor-binding proteins in a primitive, ictalurid, teleost (Ictalurus punctatus). | General and comparative endocrinology 20031101 |
| PEGylation of growth hormone-releasing hormone (GRF) analogues. | Advanced drug delivery reviews 20030926 |
| GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. | Life sciences 20030418 |
| Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. | Regulatory peptides 20030328 |
| Growth hormone releasing factor decreases long form leptin receptor expression in porcine anterior pituitary cells. | Domestic animal endocrinology 20030301 |
| Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells. | Endocrine 20020601 |
| Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. | The Journal of clinical endocrinology and metabolism 20010501 |
| The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure. | Pharmacology & toxicology 20010201 |
| Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy. | Clinical endocrinology 19980101 |
| The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. | Endocrinology 19890601 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.